Form 8-K - Current report:
SEC Accession No. 0001641172-25-015516
Filing Date
2025-06-18
Accepted
2025-06-18 08:27:34
Documents
23
Period of Report
2025-06-16
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 42893
2 EX-99.1 ex99-1.htm EX-99.1 189487
3 EX-99.2 ex99-2.htm EX-99.2 265850
4 GRAPHIC ex99-2_001.jpg GRAPHIC 39205
5 GRAPHIC ex99-2_002.jpg GRAPHIC 15508
6 GRAPHIC ex99-2_003.jpg GRAPHIC 30956
7 GRAPHIC ex99-2_004.jpg GRAPHIC 37157
8 GRAPHIC ex99-2_005.jpg GRAPHIC 52573
9 GRAPHIC ex99-2_006.jpg GRAPHIC 40731
10 GRAPHIC ex99-2_007.jpg GRAPHIC 29403
11 GRAPHIC ex99-2_008.jpg GRAPHIC 39055
  Complete submission text file 0001641172-25-015516.txt   1181763

Data Files

Seq Description Document Type Size
12 XBRL SCHEMA FILE bctx-20250616.xsd EX-101.SCH 3749
13 XBRL DEFINITION FILE bctx-20250616_def.xml EX-101.DEF 26590
14 XBRL LABEL FILE bctx-20250616_lab.xml EX-101.LAB 36630
15 XBRL PRESENTATION FILE bctx-20250616_pre.xml EX-101.PRE 25214
25 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5661
Mailing Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1
Business Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1 (604) 921-1810
BriaCell Therapeutics Corp. (Filer) CIK: 0001610820 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0731
Type: 8-K | Act: 34 | File No.: 001-40101 | Film No.: 251055223
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)